GlassScriptPhysician profile
Carlos Luis Martinez
NPI 1366476897
$41,021.20
in general payments reported to CMS, 2019-2025
57 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,516 · 2021: $10K · 2022: $1,748 · 2023: $2,371 · 2024: $2,890 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,742 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,741.94 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14,165.00 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $9,243.87 | 2019-2022 | |
| Amgen INC. | $2,306.61 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $2,165.35 | 2019-2025 | |
| Ucb, INC. | $1,504.42 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $1,432.44 | 2019-2025 | Saphnelo, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $985.81 | 2019-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $928.62 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Janssen Biotech, INC. | $752.10 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Novo Nordisk INC | $670.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $626.41 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $570.56 | 2019-2024 | Benlysta, Shingrix |
| Madrigal Pharmaceuticals | $531.73 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $474.83 | 2019-2022 | |
| Genentech USA, INC. | $402.13 | 2019-2025 | Actemra, Gazyva |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.